- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Interventions
- PCplanner
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- ORIN1001, Placebo
- Drug
- Lead sponsor
- Orinove, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 11
- States / cities
- Clearwater, Florida • Jacksonville, Florida • Pensacola, Florida + 8 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pulmonary rehabilitation
- Other
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Deupirfenidone, Pirfenidone (PFD)
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 16
- States / cities
- Palm Spring, California • Redding, California • Hialeah, Florida + 13 more
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Fibrosis Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone, Untreated Cohort
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Plymouth, Pennsylvania
- Conditions
- Lung Disease, Interstitial, Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Gefapixant
- Drug
- Lead sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Dasatinib + Quercetin, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • San Antonio, Texas
- Conditions
- Lung Transplant, CMV
- Interventions
- Letermovir, Valganciclovir
- Drug
- Lead sponsor
- Fernanda P Silveira, MD, MS
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
- Other · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- Placebo, CNTO 888 1 mg/kg, CNTO 888 5 mg/kg, CNTO 888 15 mg/kg
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- LTI-03, Dry Powder Inhaler, Placebo
- Drug · Device
- Lead sponsor
- Rein Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- 20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
- Drug · Other
- Lead sponsor
- Cellular Sciences, inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Hialeah Gardens, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809, Knottin tracer
- Drug · Radiation
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Ifetroban Sodium, Placebo
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 20
- States / cities
- La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- BG00011, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 10
- States / cities
- San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more
- Conditions
- Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- Winter Park, Florida • Skokie, Illinois • Muncie, Indiana + 4 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Physical exercise training, Cognitive exercise training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- SAR156597, Placebo (for SAR156597)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 11
- States / cities
- Sacramento, California • Jacksonville, Florida • Chicago, Illinois + 7 more
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
- Interventions
- bosentan
- Drug
- Lead sponsor
- Rajan Saggar
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Los Angeles, California